BenevolentAI
AI-based drug discovery firm BenevolentAI cuts SPAC deal
Phil Taylor
artificial intelligence, BenevolentAI, digital, digital health, M&A, SPAC
0 Comment
Digital/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
COVID heralds a faster future for drug development (if stakeholders can collaborate)
George Underwood
BenevolentAI, BIOS, data, WIRED Health
0 Comment
New research from BenovelentAI supports use of Lilly’s Olumiant in COVID-19
Richard Staines
artificial intelligence, BenevolentAI, COVID-19, Eli Lilly
0 Comment
AZ researches kidney and lung drugs with BenevolentAI
Richard Staines
artificial intelligence, AstraZeneca, BenevolentAI, chronic kidney disease, idiopathic pulmonary fibrosis
0 Comment
BenevolentAI and charities to seek macular degeneration cure
Andrew McConaghie
AI, BenevolentAI, drug discovery
0 Comment
Digital/ Digital and Social Media/ News/ News/ Top stories/ UK & Europe
Budget 2017: Artificial Intelligence funds welcome, but bolder vision needed
Marco Ricci
AI, BenevolentAI, Budget 2017, digital health
0 Comment
UK AI leader welcomes increased investment but suggests more needs to be done.
Digital and Social Media/ News/ R&D
AI-discovered candidates show promise in ALS
Marco Ricci
AI, ALS, artificial intelligence, BenevolentAI, motor neurone disease
0 Comment
Candidates slow down motor neurone death in patient samples.